VXRT.US
id: 351
N.D. California
Court06/15/2020
Class period Start08/19/2020
Class period End01/31/2023
Claim deadlineIn re VAXART, INC. SECURITIES LITIGATION.
Vaxart Inc. (VXRT) agreed to pay $12 million to settle a securities class action lawsuit.
The complaint alleged a fraudulent scheme to profit from artificially inflating the Company’s stock price by announcing false and misleading information concerning Vaxart’s oral COVID-19 vaccine candidate.
Specifically, the Complaint alleged that on June 26, 2020, Vaxart issued a press release entitled, “Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed,” falsely claiming its vaccine had been selected to participate in a non-human challenge study, organized and funded by OWS.
The Complaint alleged that on July 25, 2020, details emerged revealing the Company and its Leaders' deception concerning their alleged pump and dump scheme. In particular, on July 25, 2020, The New York Times published an article entitled, “Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine,” covering suspiciously timed stock bets that had generated significant profits for senior executives and board members at companies developing vaccines and treatments. Vaxart was featured prominently in the article, and it clarified “Vaxart is not among the companies selected to receive significant financial support from Warp Speed.”
Vaxart (VXRT) agreed to settle with investors to avoid further litigation.
Case Status
Disbursed
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
Wei Huang, Langdon Elliot, Ani Hovhannisyan
Attorneys
Hagens Berman Sobol Shapiro LLP, Scott + Scott Attorneys
Judge
Hon. Vince Chhabria
Administrator
A.B. Data Ltd
Court hearing date
01/12/2023
Trades matching type
FIFO
+$12,015,000
Cash Settlement Amount